Table 1.
The role and regulatory mechanism of m6A regulator in cancer drug resistance.
| m6A regulator | Cancer type | Role in cancer | Expressions in cancer drug resistance | Drug | Target genes | Mechanism | Ref |
|---|---|---|---|---|---|---|---|
| ALKBH5 | OSCC | Oncogene | High | Cisplatin | FOXM1 | ALKBH5 promoted FOXM1 expression by demethylating its nascent transcripts | (60) |
| ALKBH5 | OS | NA | High | Doxorubicin | NA | NA | (61) |
| ALKBH5 | PC | Tumor suppressor | Low | Gemcitabine | WIF-1 | ALKBH5 promoted WIF-1 transcription to hinder Wnt signaling | (62) |
| ALKBH5 | OC | Oncogene | Low | Olaparib | FZD10 | Silencing m6A demethylases ALKBH5, and FTO contributes to FZD10 upregulation | (57) |
| FTO | CSCC | Oncogene | High | Cisplatin | β-Catenin | FTO promoted gene expression of β-catenin via m6A modification | (63) |
| FTO | Leukemia | Oncogene | High | Imatinib, nilotinib, or PKC412 | MERTK and BCL-2 | m6A demethylated by FTO promoted MERTK and BCL-2 stability | (58) |
| FTO | OC | NA | Low | Olaparib | FZD10 | Silencing m6A demethylases ALKBH5, and FTO contributes to FZD10 upregulation | (57) |
| HNRNPA2/B1 | BC | NA | High | 4-Hydroxytamoxifen, fulvestrant | MiR-29a-3p, miR-29b-3p, miR-222, miR-1266-5p, miR-1268a, and miR-671-3p | NA | (64) |
| IGF2BP2 | OC | NA | High | Olaparib | NA | NA | (57) |
| METTL14 | OC | NA | Low | Olaparib | NA | NA | (57) |
| METTL3 | HCC | Oncogene | High | Adriamycin | ERRγ | Mettl3 delayed the half-life of precursor mRNA of ERRγ | (59) |
| METTL3 | GC | Oncogene | NA | Cisplatin | ARHGAP5 | ARHGAP5-AS1 recruits METTL3 to stimulate m6A modification of ARHGAP5 mRNA to stabilize ARHGAP5 mRNA | (65) |
| METTL3 | NPC | Oncogene | High | Cisplatin | TRIM11 | METTL3 promoted TRIM11 transcript stability via the m6A-IGF2BP2-dependent pathway | (66) |
| METTL3 | NSCLC | Oncogene | NA | Cisplatin | YAP | METTL3 enhanced the translation of YAP mRNA by recruiting YTHDF1/3 and eIF3b | (52) |
| METTL3 | Seminoma | NA | High | Cisplatin | TFAP2C | METTL3 enhances TFAP2C mRNA stability | (67) |
| METTL3 | CRC | Oncogene | NA | Doxorubicin | p53 | m6A modified by METTL3 promoted pre-mRNA splicing | (68) |
| METTL3 | OC | Oncogene | Low | Olaparib | NA | NA | (57) |
| METTL3 | CRC | Oncogene | NA | Oxaliplatin or irinotecan | CBX8 | METTL3 enhanced CBX8 mRNA stability through a IGF2BP1-dependent mechanism | (69) |
| METTL3 | HCC | Oncogene | Low | Sorafenib | FOXO3 | METTL3 promoted FOXO3 stability through a YTHDF1-dependent mechanism | (70) |
| METTL3 | OS | Oncogene | High | Doxorubicin | NA | NA | (61) |
| YTHDF1 | OC | Oncogene | No difference | Cisplatin | TRIM29 | YTHDF1 promoted TRIM29 translation | (71) |
| YTHDF1 | NSCLC | Oncogene | Low | Cisplatin | Keap1 | YTHDF1 promoted translational efficiency of Keap1 | (72) |
| YTHDF2 | OC | NA | Low | Olaparib | NA | NA | (57) |
NA, not reported.